Advanced Proteome Th (APTCF) 0.2364 $APTCF
Advanced Proteome Therapeutics Expands Anticancer Studies Base D on Strong Initial Results
Marketwire - Tue Aug 12, 8:28AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has expanded and accelerated its anticancer studies to strengthen their commercial prospects because recent positive results with collaborators have demonstrated that modifications of APC's protein delivery system substantially increases antitumor activity and retards tumor growth in animals.
Advanced Proteome Therapeutics Reports Impressive Anticancer Activity
Marketwire - Wed Mar 05, 1:10PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) has been preparing several series of potential anticancer agents, each of which has its own individual attributes for drug development as novel proprietary agents.
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Frost & Sullivan: Medical Robots Will Revolutionize Most Surgical Disciplines
M2 - Tue Feb 25, 6:34AM CST
Surgical robots are gaining widespread acceptance across the globe as they enhance the surgeons abilities in terms of surgical imaging, navigation, planning and instrument manipulation. Market participants are conducting extensive research in this field to further strengthen the capabilities of surgeons through advanced imaging techniques, higher degrees of freedom, interactive interfaces, haptics feedback, and teleoperation. Surgical robot manufacturers are also trying to reduce the footprint of existing robotic systems and lessen the invasiveness of surgical procedures by advancing single port, natural orifice, and swarm robotic technologies.
Advanced Proteome Therapeutics Corp. (APC) Provides Update on Ongoing Activities
Marketwire - Thu Dec 19, 1:07PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) is pleased to announce that through calendar year 2013 the Company has been applying its enabling Foundation Trinity(TM) Technology to proteins targeted for the treatment of cancers. Advanced, targeted therapies are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future. APC's technology will enable not only therapy targeted for tumor cells, but also the delivery of combination therapy in a single, pure therapeutic agent. To achieve this, it has been the Company's intention to utilize a unique protein, not only as a delivery system to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. What is more, the protein itself appears to possess immunotherapeutic properties. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry. This vision, the unique nature of the protein, and the ability to apply its proprietary enabling chemical technology to modification of the protein, differentiate APC from the competition.
Advanced Proteome Therapeutics Announces Agreement With Stanford University School of Medicine for Testing of Foundation Trinity(TM) Technology
Marketwire - Mon May 13, 7:43AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) is pleased to announce that it has executed an agreement with the Stanford University School of Medicine, Department of Radiology, to test protein conjugates and multimers as part of APC's "Foundation Trinity(TM)" technology involving targeted, combination, and homogeneous therapy in a single anti-cancer agent. Stanford will be testing APC's protein modifications to determine their effects on tumors in a variety of cancer disease states.
Advanced Proteome Announces Agreement With The University of Iowa for Testing of Foundation Trinity(TM) Technology
Marketwire - Mon Apr 29, 7:40AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) is pleased to announce that it has executed an agreement with The University of Iowa on behalf of Dr. Joel Shilyansky for the testing of protein conjugates and multimers as part of APC's "Foundation Trinity(TM)" technology. Dr. Shilyansky holds the Robert and Helene Soper Chair of Pediatric Surgery at the University of Iowa Carver College of Medicine. Dr. Shilyansky will be performing the testing of APC's protein modifications in the University of Iowa laboratories to determine their effects on tumor growth and immunogenicity. A focal point of his interest is the protection from tumor challenge, afforded by proteins with high affinity for cancers cells, through immune-mediated mechanisms.
Advanced Proteome Therapeutics Corporation Prepares Proprietary Protein Conjugates to Be Tested for Anti-Cancer Activities
Marketwire - Thu Mar 14, 10:30AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) announced today that it has achieved the preparation of certain novel, proprietary protein conjugates and multimers that the Company has designed for testing as anticancer agents. (A protein conjugate is a protein that is linked to a non-protein. A multimer is a substance in which more than one protein is linked together.) Using APC technologies, the Company has applied synthetic methods that are site-specific and thus permit the production of homogeneous products, which represent the gold standard of purity in the industry.
Break Out Stocks - Stocks Touching 52 Week Highs/Lows on Two Consecutive Days (NYSE: SRT) (TSXV: APC)
ACCESSWIRE-TNW - Thu Feb 28, 8:37AM CST
Toronto, Canada: : In tracking the small cap stock universe of US and Canadian stocks for Wednesday, February 27, 2013, Ubika Research based on the proprietary criteria found that the following companies touched 52 week highs or lows for 2 consecutive days during the trading session: StarTek Inc. (NYSE: SRT), Advanced Proteome Therapeutics Corp. (TSX VENTURE: APC) (CVE: APC) among others.
Ubika Research's Daily Canadian Box Score: Top Junior Diversified Mining (CNSX: XBR) Stock Gained 25%
ACCESSWIRE-TNW - Thu Feb 28, 8:32AM CST
TORONTO, Canada: In tracking the small cap stock universe of Canadian stocks based on proprietary criteria for Wednesday, February 27, 2013, Ubika Research found the top small cap stock gainers from each of the following sectors.
Advanced Proteome Therapeutics Corp. (APC) Announces New Directions in Cancer Therapies
Marketwire - Mon Feb 25, 7:27AM CST
Preparation and testing of innovative, homogeneous drugs: combining multiple therapies by linking them to a protein which is directly targeted to cancer tumors and has been shown to promote anti-tumor immunity. The Advanced Protein Conjugate Therapeutic (APCT).
Advanced Proteome Therapeutics Expands Anticancer Studies Base D on Strong Initial Results
Marketwire - Tue Aug 12, 8:28AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has expanded and accelerated its anticancer studies to strengthen their commercial prospects because recent positive results with collaborators have demonstrated that modifications of APC's protein delivery system substantially increases antitumor activity and retards tumor growth in animals. Advanced Proteome Therapeutics Reports Impressive Anticancer Activity
Marketwire - Wed Mar 05, 1:10PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) has been preparing several series of potential anticancer agents, each of which has its own individual attributes for drug development as novel proprietary agents. Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Frost & Sullivan: Medical Robots Will Revolutionize Most Surgical Disciplines
M2 - Tue Feb 25, 6:34AM CST
Surgical robots are gaining widespread acceptance across the globe as they enhance the surgeons abilities in terms of surgical imaging, navigation, planning and instrument manipulation. Market participants are conducting extensive research in this field to further strengthen the capabilities of surgeons through advanced imaging techniques, higher degrees of freedom, interactive interfaces, haptics feedback, and teleoperation. Surgical robot manufacturers are also trying to reduce the footprint of existing robotic systems and lessen the invasiveness of surgical procedures by advancing single port, natural orifice, and swarm robotic technologies.
Advanced Proteome Therapeutics Corp. (APC) Provides Update on Ongoing Activities
Marketwire - Thu Dec 19, 1:07PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) is pleased to announce that through calendar year 2013 the Company has been applying its enabling Foundation Trinity(TM) Technology to proteins targeted for the treatment of cancers. Advanced, targeted therapies are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future. APC's technology will enable not only therapy targeted for tumor cells, but also the delivery of combination therapy in a single, pure therapeutic agent. To achieve this, it has been the Company's intention to utilize a unique protein, not only as a delivery system to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. What is more, the protein itself appears to possess immunotherapeutic properties. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry. This vision, the unique nature of the protein, and the ability to apply its proprietary enabling chemical technology to modification of the protein, differentiate APC from the competition. Advanced Proteome Therapeutics Announces Agreement With Stanford University School of Medicine for Testing of Foundation Trinity(TM) Technology
Marketwire - Mon May 13, 7:43AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) is pleased to announce that it has executed an agreement with the Stanford University School of Medicine, Department of Radiology, to test protein conjugates and multimers as part of APC's "Foundation Trinity(TM)" technology involving targeted, combination, and homogeneous therapy in a single anti-cancer agent. Stanford will be testing APC's protein modifications to determine their effects on tumors in a variety of cancer disease states. Advanced Proteome Announces Agreement With The University of Iowa for Testing of Foundation Trinity(TM) Technology
Marketwire - Mon Apr 29, 7:40AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) is pleased to announce that it has executed an agreement with The University of Iowa on behalf of Dr. Joel Shilyansky for the testing of protein conjugates and multimers as part of APC's "Foundation Trinity(TM)" technology. Dr. Shilyansky holds the Robert and Helene Soper Chair of Pediatric Surgery at the University of Iowa Carver College of Medicine. Dr. Shilyansky will be performing the testing of APC's protein modifications in the University of Iowa laboratories to determine their effects on tumor growth and immunogenicity. A focal point of his interest is the protection from tumor challenge, afforded by proteins with high affinity for cancers cells, through immune-mediated mechanisms. Advanced Proteome Therapeutics Corporation Prepares Proprietary Protein Conjugates to Be Tested for Anti-Cancer Activities
Marketwire - Thu Mar 14, 10:30AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) announced today that it has achieved the preparation of certain novel, proprietary protein conjugates and multimers that the Company has designed for testing as anticancer agents. (A protein conjugate is a protein that is linked to a non-protein. A multimer is a substance in which more than one protein is linked together.) Using APC technologies, the Company has applied synthetic methods that are site-specific and thus permit the production of homogeneous products, which represent the gold standard of purity in the industry. Break Out Stocks - Stocks Touching 52 Week Highs/Lows on Two Consecutive Days (NYSE: SRT) (TSXV: APC)
ACCESSWIRE-TNW - Thu Feb 28, 8:37AM CST
Toronto, Canada: : In tracking the small cap stock universe of US and Canadian stocks for Wednesday, February 27, 2013, Ubika Research based on the proprietary criteria found that the following companies touched 52 week highs or lows for 2 consecutive days during the trading session: StarTek Inc. (NYSE: SRT), Advanced Proteome Therapeutics Corp. (TSX VENTURE: APC) (CVE: APC) among others.
Ubika Research's Daily Canadian Box Score: Top Junior Diversified Mining (CNSX: XBR) Stock Gained 25%
ACCESSWIRE-TNW - Thu Feb 28, 8:32AM CST
TORONTO, Canada: In tracking the small cap stock universe of Canadian stocks based on proprietary criteria for Wednesday, February 27, 2013, Ubika Research found the top small cap stock gainers from each of the following sectors.
Advanced Proteome Therapeutics Corp. (APC) Announces New Directions in Cancer Therapies
Marketwire - Mon Feb 25, 7:27AM CST
Preparation and testing of innovative, homogeneous drugs: combining multiple therapies by linking them to a protein which is directly targeted to cancer tumors and has been shown to promote anti-tumor immunity. The Advanced Protein Conjugate Therapeutic (APCT).
